-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since April, the executives of pharmaceutical companies have changed frequently, including the deputy general manager of Hengrui, the deputy general manager of Ruikang Pharmaceutical, the chairman of Xinbang Pharmaceutical, the vice president of Lanfan Medical, the independent director of Rongchang Bio, and the employee supervisor of Guangyuyuan.
, director of Foci Pharmaceuticals, several senior executives of Jingfeng Pharmaceutical, etc.
; multinational, there have also been personnel changes in 3 pharmaceutical companies recently, namely Novartis, Bayer and Boehringer Ingelheim
.
Novartis: Changes in multiple executives On April 24, Novartis confirmed the international regional heads of innovative drugs.
Among them, Zhang Ying, president of Novartis Pharmaceuticals (China), was appointed as president and managing director of innovative drugs China.
effective from today
.
On the same day, Novartis also appointed a number of other regional heads, including Irism Zemzoumi, current president of Novartis Pharma Asia Pacific, Middle East and Africa (APMA), will serve as president of Novartis Innovative Medicines APMA, and Leo Lee, currently head of Novartis Pharma Japan and president of Novartis Japan, will serve as the president.
President and Managing Director of Novartis Innovative Medicines Japan, effective June 1
.
In addition, effective July 15, Pasquale Frega, currently president of Novartis Italy and head of the pharmaceutical business, will serve as president of Novartis Innovative Medicines Latin America and Canada (LACan)
.
Behind the adjustment of Novartis' executives, it is mainly related to the adjustment of the company's business and structure
.
In early April, Novartis announced that it would integrate the two business divisions of pharmaceuticals and oncology, merge into one innovative drug division, and create two independent commercial organizations, which will be divided into two major commercial divisions, the US and the international division, and the new two divisions.
It will operate independently, conduct independent accounting, and be fully responsible for all therapeutic areas
.
In addition, according to the news previously announced by Novartis Global, comprehensive administrative functions such as finance, personnel, compliance, legal affairs, and communication will also be globally integrated and integrated at the global and national and regional levels
.
From the perspective of the industry, after the merger of the two Novartis business units, related personnel changes and adjustments are inevitable, and executive changes are also reasonable.
.
Bayer: Poaching a GSK executive Recently, Bayer appointed Dr.
Tara Frenkl to lead its oncology strategic business unit, effective April 25, reporting directly to Christine Roth
.
According to the data, Tara Frenkl once served as senior vice president and head of oncology drug development at GlaxoSmithKline.
After joining Bayer, he will focus on the development of prostate cancer drug Nubeqa with Roth
.
Nubeqa (darolutamide) is an androgen receptor inhibitor approved by the FDA in 2019 for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)
.
However, due to the impact of powerful rivals and the impact of the epidemic, Bayer's third-quarter 2021 results show that Nubeqa sales growth is slow
.
Boehringer Ingelheim: Change of Vice President of Human Resources for BI Greater China On April 22, Boehringer Ingelheim also reported the change of senior management, because the current Vice President of Human Resources of BI Greater China, Guan Hongjuan, decided to retire.
From the 1st, Xie Fang, the current human resources business partner of BI Greater China Human and Pharmaceutical Division, will take over the position of Vice President of Human Resources of BI Greater China, join the leadership team of BI Greater China, and become a member of BI Global Human Resources Committee.
Based in Shanghai, he reports directly to Gao Qifei, CEO and President of BI Greater China, and reports to Sven Sommerlatte, Head of BI Global Human Resources
.
According to the data, Xie Fang has joined Boehringer Ingelheim for more than ten years and has extensive experience in the fields of human resources shared services, compensation and benefits, and human resources business partners
.
During his tenure as the human resources business partner of BI Greater China Human and Pharmaceutical Division, he was responsible for the formulation and implementation of the human resources strategy of the Greater China Human and Pharmaceutical Division.
At the same time, he played a key role in the business transformation of the Human and Pharmaceutical Division - Riding the Wind and Waves Project
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, director of Foci Pharmaceuticals, several senior executives of Jingfeng Pharmaceutical, etc.
; multinational, there have also been personnel changes in 3 pharmaceutical companies recently, namely Novartis, Bayer and Boehringer Ingelheim
.
Novartis: Changes in multiple executives On April 24, Novartis confirmed the international regional heads of innovative drugs.
Among them, Zhang Ying, president of Novartis Pharmaceuticals (China), was appointed as president and managing director of innovative drugs China.
effective from today
.
On the same day, Novartis also appointed a number of other regional heads, including Irism Zemzoumi, current president of Novartis Pharma Asia Pacific, Middle East and Africa (APMA), will serve as president of Novartis Innovative Medicines APMA, and Leo Lee, currently head of Novartis Pharma Japan and president of Novartis Japan, will serve as the president.
President and Managing Director of Novartis Innovative Medicines Japan, effective June 1
.
In addition, effective July 15, Pasquale Frega, currently president of Novartis Italy and head of the pharmaceutical business, will serve as president of Novartis Innovative Medicines Latin America and Canada (LACan)
.
Behind the adjustment of Novartis' executives, it is mainly related to the adjustment of the company's business and structure
.
In early April, Novartis announced that it would integrate the two business divisions of pharmaceuticals and oncology, merge into one innovative drug division, and create two independent commercial organizations, which will be divided into two major commercial divisions, the US and the international division, and the new two divisions.
It will operate independently, conduct independent accounting, and be fully responsible for all therapeutic areas
.
In addition, according to the news previously announced by Novartis Global, comprehensive administrative functions such as finance, personnel, compliance, legal affairs, and communication will also be globally integrated and integrated at the global and national and regional levels
.
From the perspective of the industry, after the merger of the two Novartis business units, related personnel changes and adjustments are inevitable, and executive changes are also reasonable.
.
Bayer: Poaching a GSK executive Recently, Bayer appointed Dr.
Tara Frenkl to lead its oncology strategic business unit, effective April 25, reporting directly to Christine Roth
.
According to the data, Tara Frenkl once served as senior vice president and head of oncology drug development at GlaxoSmithKline.
After joining Bayer, he will focus on the development of prostate cancer drug Nubeqa with Roth
.
Nubeqa (darolutamide) is an androgen receptor inhibitor approved by the FDA in 2019 for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)
.
However, due to the impact of powerful rivals and the impact of the epidemic, Bayer's third-quarter 2021 results show that Nubeqa sales growth is slow
.
Boehringer Ingelheim: Change of Vice President of Human Resources for BI Greater China On April 22, Boehringer Ingelheim also reported the change of senior management, because the current Vice President of Human Resources of BI Greater China, Guan Hongjuan, decided to retire.
From the 1st, Xie Fang, the current human resources business partner of BI Greater China Human and Pharmaceutical Division, will take over the position of Vice President of Human Resources of BI Greater China, join the leadership team of BI Greater China, and become a member of BI Global Human Resources Committee.
Based in Shanghai, he reports directly to Gao Qifei, CEO and President of BI Greater China, and reports to Sven Sommerlatte, Head of BI Global Human Resources
.
According to the data, Xie Fang has joined Boehringer Ingelheim for more than ten years and has extensive experience in the fields of human resources shared services, compensation and benefits, and human resources business partners
.
During his tenure as the human resources business partner of BI Greater China Human and Pharmaceutical Division, he was responsible for the formulation and implementation of the human resources strategy of the Greater China Human and Pharmaceutical Division.
At the same time, he played a key role in the business transformation of the Human and Pharmaceutical Division - Riding the Wind and Waves Project
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
